Search

Your search keyword '"Visser, Pieter Jelle"' showing total 2,031 results
Start Over Author "Visser, Pieter Jelle"
2,031 results on '"Visser, Pieter Jelle"'

2. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

Author

Delvenne, Aurore, Vandendriessche, Charysse, Gobom, Johan, Burgelman, Marlies, Dujardin, Pieter, De Nolf, Clint, Tijms, Betty M., Teunissen, Charlotte E., Schindler, Suzanne E., Verhey, Frans, Ramakers, Inez, Martinez-Lage, Pablo, Tainta, Mikel, Vandenberghe, Rik, Schaeverbeke, Jolien, Engelborghs, Sebastiaan, De Roeck, Ellen, Popp, Julius, Peyratout, Gwendoline, Tsolaki, Magda, Freund-Levi, Yvonne, Lovestone, Simon, Streffer, Johannes, Bertram, Lars, Blennow, Kaj, Zetterberg, Henrik, Visser, Pieter Jelle, Vandenbroucke, Roosmarijn E., and Vos, Stephanie J. B.

Published
2024
Full Text
View/download PDF

3. Amyloid-PET imaging predicts functional decline in clinically normal individuals

Author

Quenon, Lisa, Collij, Lyduine E., Garcia, David Vállez, Lopes Alves, Isadora, Gérard, Thomas, Malotaux, Vincent, Huyghe, Lara, Gispert, Juan Domingo, Jessen, Frank, Visser, Pieter Jelle, den Braber, Anouk, Ritchie, Craig W., Boada, Mercè, Marquié, Marta, Vandenberghe, Rik, Luckett, Emma S., Schöll, Michael, Frisoni, Giovanni B., Buckley, Christopher, Stephens, Andrew, Altomare, Daniele, Ford, Lisa, Birck, Cindy, Mett, Anja, Gismondi, Rossella, Wolz, Robin, Grootoonk, Sylke, Manber, Richard, Shekari, Mahnaz, Lhommel, Renaud, Dricot, Laurence, Ivanoiu, Adrian, Farrar, Gill, Barkhof, Frederik, and Hanseeuw, Bernard J.

Published
2024
Full Text
View/download PDF

4. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles

Author

Tijms, Betty M., Vromen, Ellen M., Mjaavatten, Olav, Holstege, Henne, Reus, Lianne M., van der Lee, Sven, Wesenhagen, Kirsten E. J., Lorenzini, Luigi, Vermunt, Lisa, Venkatraghavan, Vikram, Tesi, Niccoló, Tomassen, Jori, den Braber, Anouk, Goossens, Julie, Vanmechelen, Eugeen, Barkhof, Frederik, Pijnenburg, Yolande A. L., van der Flier, Wiesje M., Teunissen, Charlotte E., Berven, Frode S., and Visser, Pieter Jelle

Published
2024
Full Text
View/download PDF

5. Outcome measures for Alzheimer's disease: A global inter‐societal Delphi consensus

Author

Ellison, Tim S, Cappa, Stefano F, Garrett, Dawne, Georges, Jean, Iwatsubo, Takeshi, Kramer, Joel H, Lehmann, Maryna, Lyketsos, Constantine, Maier, Andrea B, Merrilees, Jennifer, Morris, John C, Naismith, Sharon L, Nobili, Flavio, Pahor, Marco, Pond, Dimity, Robinson, Louise, Soysal, Pinar, Vandenbulcke, Mathieu, Weber, Christopher J, Visser, Pieter Jelle, Weiner, Michael, and Frisoni, Giovanni B

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Psychology, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Dementia, Neurodegenerative, Alzheimer's Disease, Aging, Brain Disorders, Behavioral and Social Science, Acquired Cognitive Impairment, Clinical Research, Health Services, Neurosciences, Neurological, Humans, Alzheimer Disease, Quality of Life, Consensus, Delphi Technique, Outcome Assessment, Health Care, Alzheimer's disease, consensus, Delphi, dementia, measures, outcomes, Geriatrics, Clinical sciences, Biological psychology
Abstract

IntroductionWe aim to provide guidance on outcomes and measures for use in patients with Alzheimer's clinical syndrome.MethodsA consensus group of 20 voting members nominated by 10 professional societies, and a non-voting chair, used a Delphi approach and modified GRADE criteria.ResultsConsensus was reached on priority outcomes (n = 66), measures (n = 49) and statements (n = 37) across nine domains. A number of outcomes and measurement instruments were ranked for: Cognitive abilities; Functional abilities/dependency; Behavioural and neuropsychiatric symptoms; Patient quality of life (QoL); Caregiver QoL; Healthcare and treatment-related outcomes; Medical investigations; Disease-related life events; and Global outcomes.DiscussionThis work provides indications on the domains and ideal pertinent measurement instruments that clinicians may wish to use to follow patients with cognitive impairment. More work is needed to develop instruments that are more feasible in the context of the constraints of clinical routine.

Published
2023

6. Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease

Author

Holstege, Henne, Hulsman, Marc, Charbonnier, Camille, Grenier-Boley, Benjamin, Quenez, Olivier, Grozeva, Detelina, van Rooij, Jeroen GJ, Sims, Rebecca, Ahmad, Shahzad, Amin, Najaf, Norsworthy, Penny J, Dols-Icardo, Oriol, Hummerich, Holger, Kawalia, Amit, Amouyel, Philippe, Beecham, Gary W, Berr, Claudine, Bis, Joshua C, Boland, Anne, Bossù, Paola, Bouwman, Femke, Bras, Jose, Campion, Dominique, Cochran, J Nicholas, Daniele, Antonio, Dartigues, Jean-François, Debette, Stéphanie, Deleuze, Jean-François, Denning, Nicola, DeStefano, Anita L, Farrer, Lindsay A, Fernández, Maria Victoria, Fox, Nick C, Galimberti, Daniela, Genin, Emmanuelle, Gille, Johan JP, Le Guen, Yann, Guerreiro, Rita, Haines, Jonathan L, Holmes, Clive, Ikram, M Arfan, Ikram, M Kamran, Jansen, Iris E, Kraaij, Robert, Lathrop, Marc, Lemstra, Afina W, Lleó, Alberto, Luckcuck, Lauren, Mannens, Marcel MAM, Marshall, Rachel, Martin, Eden R, Masullo, Carlo, Mayeux, Richard, Mecocci, Patrizia, Meggy, Alun, Mol, Merel O, Morgan, Kevin, Myers, Richard M, Nacmias, Benedetta, Naj, Adam C, Napolioni, Valerio, Pasquier, Florence, Pastor, Pau, Pericak-Vance, Margaret A, Raybould, Rachel, Redon, Richard, Reinders, Marcel JT, Richard, Anne-Claire, Riedel-Heller, Steffi G, Rivadeneira, Fernando, Rousseau, Stéphane, Ryan, Natalie S, Saad, Salha, Sanchez-Juan, Pascual, Schellenberg, Gerard D, Scheltens, Philip, Schott, Jonathan M, Seripa, Davide, Seshadri, Sudha, Sie, Daoud, Sistermans, Erik A, Sorbi, Sandro, van Spaendonk, Resie, Spalletta, Gianfranco, Tesi, Niccolo’, Tijms, Betty, Uitterlinden, André G, van der Lee, Sven J, Visser, Pieter Jelle, Wagner, Michael, Wallon, David, Wang, Li-San, Zarea, Aline, Clarimon, Jordi, van Swieten, John C, Greicius, Michael D, Yokoyama, Jennifer S, Cruchaga, Carlos, Hardy, John, and Ramirez, Alfredo

Subjects
Biological Sciences, Genetics, Dementia, Alzheimer's Disease, Neurosciences, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Human Genome, Prevention, Acquired Cognitive Impairment, Neurodegenerative, Aging, Clinical Research, Biotechnology, Brain Disorders, 2.1 Biological and endogenous factors, Aetiology, Neurological, Humans, Adenosine Triphosphatases, Alzheimer Disease, ATP Binding Cassette Transporter 1, Genome-Wide Association Study, Risk Factors, Exosomes, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Alzheimer's disease (AD), the leading cause of dementia, has an estimated heritability of approximately 70%1. The genetic component of AD has been mainly assessed using genome-wide association studies, which do not capture the risk contributed by rare variants2. Here, we compared the gene-based burden of rare damaging variants in exome sequencing data from 32,558 individuals-16,036 AD cases and 16,522 controls. Next to variants in TREM2, SORL1 and ABCA7, we observed a significant association of rare, predicted damaging variants in ATP8B4 and ABCA1 with AD risk, and a suggestive signal in ADAM10. Additionally, the rare-variant burden in RIN3, CLU, ZCWPW1 and ACE highlighted these genes as potential drivers of respective AD-genome-wide association study loci. Variants associated with the strongest effect on AD risk, in particular loss-of-function variants, are enriched in early-onset AD cases. Our results provide additional evidence for a major role for amyloid-β precursor protein processing, amyloid-β aggregation, lipid metabolism and microglial function in AD.

Published
2022

7. Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies

Author

Twait, Emma L., Kamarioti, Maria, Verberk, Inge M.W., Teunissen, Charlotte E., Nooyens, Astrid C.J., Monique Verschuren, W.M., Visser, Pieter Jelle, Huisman, Martijn, Kok, Almar A.L., Eline Slagboom, P., Beekman, Marian, Vojinovic, Dina, Lakenberg, Nico, Arfan Ikram, M., Schuurmans, Isabel K., Wolters, Frank J., Moonen, Justine E.F., Gerritsen, Lotte, van der Flier, Wiesje M., and Geerlings, Mirjam I.

Published
2024
Full Text
View/download PDF

8. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

Author

Gómez-Pascual, Alicia, Naccache, Talel, Xu, Jin, Hooshmand, Kourosh, Wretlind, Asger, Gabrielli, Martina, Lombardo, Marta Tiffany, Shi, Liu, Buckley, Noel J., Tijms, Betty M., Vos, Stephanie J.B., ten Kate, Mara, Engelborghs, Sebastiaan, Sleegers, Kristel, Frisoni, Giovanni B., Wallin, Anders, Lleó, Alberto, Popp, Julius, Martinez-Lage, Pablo, Streffer, Johannes, Barkhof, Frederik, Zetterberg, Henrik, Visser, Pieter Jelle, Lovestone, Simon, Bertram, Lars, Nevado-Holgado, Alejo J., Gualerzi, Alice, Picciolini, Silvia, Proitsi, Petroula, Verderio, Claudia, Botía, Juan A., and Legido-Quigley, Cristina

Published
2024
Full Text
View/download PDF

10. Augmented reality versus standard tests to assess cognition and function in early Alzheimer’s disease

Author

Muurling, Marijn, de Boer, Casper, Vairavan, Srinivasan, Harms, Robbert L., Chadha, Antonella Santuccione, Tarnanas, Ioannis, Luis, Estefania Vilarino, Religa, Dorota, Gjestsen, Martha Therese, Galluzzi, Samantha, Ibarria Sala, Marta, Koychev, Ivan, Hausner, Lucrezia, Gkioka, Mara, Aarsland, Dag, Visser, Pieter Jelle, and Brem, Anna-Katharine

Published
2023
Full Text
View/download PDF

12. Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

Author

Bader, Ilse, Bader, Ilona, Lopes Alves, Isadora, Vállez García, David, Vellas, Bruno, Dubois, Bruno, Boada, Mercè, Marquié, Marta, Altomare, Daniele, Scheltens, Philip, Vandenberghe, Rik, Hanseeuw, Bernard, Schöll, Michael, Frisoni, Giovanni B., Jessen, Frank, Nordberg, Agneta, Kivipelto, Miia, Ritchie, Craig W., Grau-Rivera, Oriol, Molinuevo, José Luis, Ford, Lisa, Stephens, Andrew, Gismondi, Rossella, Gispert, Juan Domingo, Farrar, Gill, Barkhof, Frederik, Visser, Pieter Jelle, and Collij, Lyduine E.

Published
2023
Full Text
View/download PDF

14. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Author

Neumann, Alexander, Ohlei, Olena, Küçükali, Fahri, Bos, Isabelle J., Timsina, Jigyasha, Vos, Stephanie, Prokopenko, Dmitry, Tijms, Betty M., Andreasson, Ulf, Blennow, Kaj, Vandenberghe, Rik, Scheltens, Philip, Teunissen, Charlotte E., Engelborghs, Sebastiaan, Frisoni, Giovanni B., Blin, Oliver, Richardson, Jill C., Bordet, Régis, Lleó, Alberto, Alcolea, Daniel, Popp, Julius, Marsh, Thomas W., Gorijala, Priyanka, Clark, Christopher, Peyratout, Gwendoline, Martinez-Lage, Pablo, Tainta, Mikel, Dobson, Richard J. B., Legido-Quigley, Cristina, Van Broeckhoven, Christine, Tanzi, Rudolph E., ten Kate, Mara, Lill, Christina M., Barkhof, Frederik, Cruchaga, Carlos, Lovestone, Simon, Streffer, Johannes, Zetterberg, Henrik, Visser, Pieter Jelle, Sleegers, Kristel, and Bertram, Lars

Published
2023
Full Text
View/download PDF

19. Decline in cognitively complex everyday activities accelerates along the Alzheimer’s disease continuum

Author

Dubbelman, Mark A, Jutten, Roos J, Tomaszewski Farias, Sarah E, Amariglio, Rebecca E, Buckley, Rachel F, Visser, Pieter Jelle, Rentz, Dorene M, Johnson, Keith A, Properzi, Michael J, Schultz, Aaron, Donovan, Nancy, Gatchell, Jennifer R, Teunissen, Charlotte E, Van Berckel, Bart NM, Van der Flier, Wiesje M, Sperling, Reisa A, Papp, Kathryn V, Scheltens, Philip, Marshall, Gad A, and Sikkes, Sietske AM

Subjects
Health Services and Systems, Health Sciences, Aging, Neurosciences, Rehabilitation, Alzheimer's Disease, Dementia, Neurodegenerative, Acquired Cognitive Impairment, Brain Disorders, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Clinical Research, Behavioral and Social Science, Neurological, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Amyloid beta-Peptides, Cognitive Dysfunction, Disease Progression, Female, Humans, Longitudinal Studies, Male, Middle Aged, Prodromal Symptoms, Alzheimer&#8217, s disease, functional impairment, instrumental activities of daily living, clinical stages, Alzheimer Disease Neuroimaging Initiative, National Alzheimer’s Coordinating Center, the Harvard Aging Brain Study, the Alzheimer Dementia Cohort, Alzheimer’s disease, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundImpairment in daily functioning is a clinical hallmark of dementia. Difficulties with "instrumental activities of daily living" (IADL) seem to increase gradually over the course of Alzheimer's disease (AD), before dementia onset. However, it is currently not well established how difficulties develop along the preclinical and prodromal stages of AD. We aimed to investigate the trajectories of decline in IADL performance, as reported by a study partner, along the early stages of AD.MethodsIn a longitudinal multicenter study, combining data from community-based and memory clinic cohorts, we included 1555 individuals (mean age 72.5 ± 7.8 years; 50% female) based on availability of amyloid biomarkers, longitudinal IADL data, and clinical information at baseline. Median follow-up duration was 2.1 years. All amyloid-positive participants (n = 982) were classified into the National Institute on Aging-Alzheimer's Association (NIA-AA) clinical stages ranging from preclinical AD (1) to overt dementia (4+). Cognitively normal amyloid-negative individuals (n = 573) served as a comparison group. The total scores of three study-partner reported IADL questionnaires were standardized.ResultsThe rate of decline in cognitively normal (stage 1) individuals with and without abnormal amyloid did not differ (p = .453). However, from stage 2 onwards, decline was significantly faster in individuals on the AD continuum (B [95%CI] = - 0.32 [- 0.55, - 0.09], p = .007). The rate of decline increased with each successive stage: one standard deviation (SD) unit per year in stage 3 (- 1.06 [- 1.27, - 0.85], p

Published
2020

22. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

Author

Neumann, Alexander, Küçükali, Fahri, Bos, Isabelle, Vos, Stephanie J. B., Engelborghs, Sebastiaan, De Pooter, Tim, Joris, Geert, De Rijk, Peter, De Roeck, Ellen, Tsolaki, Magda, Verhey, Frans, Martinez-Lage, Pablo, Tainta, Mikel, Frisoni, Giovanni, Blin, Oliver, Richardson, Jill, Bordet, Régis, Scheltens, Philip, Popp, Julius, Peyratout, Gwendoline, Johannsen, Peter, Frölich, Lutz, Vandenberghe, Rik, Freund-Levi, Yvonne, Streffer, Johannes, Lovestone, Simon, Legido-Quigley, Cristina, ten Kate, Mara, Barkhof, Frederik, Strazisar, Mojca, Zetterberg, Henrik, Bertram, Lars, Visser, Pieter Jelle, van Broeckhoven, Christine, and Sleegers, Kristel

Published
2022
Full Text
View/download PDF

23. White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study

Author

Legdeur, Nienke, Visser, Pieter Jelle, Woodworth, Davis C, Muller, Majon, Fletcher, Evan, Maillard, Pauline, Scheltens, Philip, DeCarli, Charles, Kawas, Claudia H, and Corrada, María M

Subjects
Clinical and Health Psychology, Psychology, Brain Disorders, Aging, Clinical Research, Mental Health, Neurosciences, Behavioral and Social Science, Mental health, Neurological, Aged, 80 and over, Atrophy, Brain, Cognition, Cognitive Dysfunction, Female, Hippocampus, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Organ Size, White Matter, white matter hyperintensities, hippocampal atrophy, cognitive functioning, oldest-old, Medical and Health Sciences, Geriatrics, Biomedical and clinical sciences, Health sciences
Abstract

ObjectivesTo study the interactive effect of white matter hyperintensities (WMH) and hippocampal atrophy on cognition in the oldest old.DesignOngoing longitudinal study.SettingIn Southern California, brain magnetic resonance imaging (MRI) scans were conducted between May 2014 and December 2017.ParticipantsIndividuals from The 90+ Study with a valid brain MRI scan (N = 141; 94 cognitively normal and 47 with cognitive impairment).MeasurementsCognitive testing was performed every 6 months with a mean follow-up of 2 years and included these tests: Mini-Mental State Examination (MMSE), modified MMSE (3MS), California Verbal Learning Test (CVLT) immediate recall over four trials and delayed recall, Digit Span Backward, Animal Fluency, and Trail Making Test (TMT) A, B, and C. We used one linear mixed model for each cognitive test to study the baseline and longitudinal association of WMH and hippocampal volume (HV) with cognition. Models were adjusted for age, sex, and education.ResultsMean age was 94.3 years (standard deviation [SD] = 3.2 y). At baseline, higher WMH volumes were associated with worse scores on the 3MS, CVLT immediate and delayed recall, and TMT B. Lower HVs were associated with worse baseline scores on all cognitive tests, except for the Digit Span Backward. Longitudinally, higher WMH and lower HVs were associated with faster decline in the 3MS and MMSE, and lower HV was also associated with faster decline in the CVLT immediate recall. No association was observed between WMH and HV and no interaction between WMH and HV in their association with baseline cognition or cognitive decline.ConclusionWe show that WMH and hippocampal atrophy have an independent, negative effect on cognition that make these biomarkers relevant to evaluate in the diagnostic work-up of the oldest-old individuals with cognitive complaints. However, the predictive value of WMH for cognitive decline seems to be less evident in the oldest-old compared with a younger group of older adults. J Am Geriatr Soc 67:1827-1834, 2019.

Published
2019

24. Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

Author

Bergeron, David, Gorno‐Tempini, Maria L, Rabinovici, Gil D, Santos‐Santos, Miguel A, Seeley, William, Miller, Bruce L, Pijnenburg, Yolande, Keulen, M Antoinette, Groot, Colin, van Berckel, Bart NM, van der Flier, Wiesje M, Scheltens, Philip, Rohrer, Jonathan D, Warren, Jason D, Schott, Jonathan M, Fox, Nick C, Sanchez‐Valle, Raquel, Grau‐Rivera, Oriol, Gelpi, Ellen, Seelaar, Harro, Papma, Janne M, van Swieten, John C, Hodges, John R, Leyton, Cristian E, Piguet, Olivier, Rogalski, Emily J, Mesulam, Marsel M, Koric, Lejla, Kristensen, Nora, Pariente, Jeéreémie, Dickerson, Bradford, Mackenzie, Ian R, Hsiung, Ging‐Yuek R, Belliard, Serge, Irwin, David J, Wolk, David A, Grossman, Murray, Jones, Matthew, Harris, Jennifer, Mann, David, Snowden, Julie S, Chrem‐Mendez, Patricio, Calandri, Ismael L, Amengual, Alejandra A, Miguet‐Alfonsi, Carole, Magnin, Eloi, Magnani, Giuseppe, Santangelo, Roberto, Deramecourt, Vincent, Pasquier, Florence, Mattsson, Niklas, Nilsson, Christer, Hansson, Oskar, Keith, Julia, Masellis, Mario, Black, Sandra E, Matías‐Guiu, Jordi A, Cabrera‐Martin, María‐Nieves, Paquet, Claire, Dumurgier, Julien, Teichmann, Marc, Sarazin, Marie, Bottlaender, Michel, Dubois, Bruno, Rowe, Christopher C, Villemagne, Victor L, Vandenberghe, Rik, Granadillo, Elias, Teng, Edmond, Mendez, Mario, Meyer, Philipp T, Frings, Lars, Lleó, Alberto, Blesa, Rafael, Fortea, Juan, Seo, Sang Won, Diehl‐Schmid, Janine, Grimmer, Timo, Frederiksen, Kristian Steen, Sánchez‐Juan, Pascual, Chételat, Gaël, Jansen, Willemijn, Bouchard, Rémi W, Laforce, Robert Jr, Visser, Pieter Jelle, and Ossenkoppele, Rik

Subjects
Biomedical and Clinical Sciences, Neurosciences, Clinical Sciences, Dementia, Rare Diseases, Aging, Neurodegenerative, Brain Disorders, Frontotemporal Dementia (FTD), Clinical Research, Aphasia, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Acquired Cognitive Impairment, Alzheimer's Disease Related Dementias (ADRD), Genetics, Alzheimer's Disease, 4.2 Evaluation of markers and technologies, Aetiology, Detection, screening and diagnosis, 2.1 Biological and endogenous factors, Neurological, Age Factors, Aged, Aged, 80 and over, Amyloid beta-Peptides, Aphasia, Primary Progressive, Apolipoproteins E, Brain, Female, Genotype, Humans, Male, Middle Aged, Prevalence, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo estimate the prevalence of amyloid positivity, defined by positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers and/or neuropathological examination, in primary progressive aphasia (PPA) variants.MethodsWe conducted a meta-analysis with individual participant data from 1,251 patients diagnosed with PPA (including logopenic [lvPPA, n = 443], nonfluent [nfvPPA, n = 333], semantic [svPPA, n = 401], and mixed/unclassifiable [n = 74] variants of PPA) from 36 centers, with a measure of amyloid-β pathology (CSF [n = 600], PET [n = 366], and/or autopsy [n = 378]) available. The estimated prevalence of amyloid positivity according to PPA variant, age, and apolipoprotein E (ApoE) ε4 status was determined using generalized estimating equation models.ResultsAmyloid-β positivity was more prevalent in lvPPA (86%) than in nfvPPA (20%) or svPPA (16%; p

Published
2018

25. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

Author

Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

26. Increased CSF-decorin predicts brain pathological changes driven by Alzheimer’s Aβ amyloidosis

Author

Jiang, Richeng, Smailovic, Una, Haytural, Hazal, Tijms, Betty M., Li, Hao, Haret, Robert Mihai, Shevchenko, Ganna, Chen, Gefei, Abelein, Axel, Gobom, Johan, Frykman, Susanne, Sekiguchi, Misaki, Fujioka, Ryo, Watamura, Naoto, Sasaguri, Hiroki, Nyström, Sofie, Hammarström, Per, Saido, Takaomi C., Jelic, Vesna, Syvänen, Stina, Zetterberg, Henrik, Winblad, Bengt, Bergquist, Jonas, Visser, Pieter Jelle, and Nilsson, Per

Published
2022
Full Text
View/download PDF

27. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease

Author

Visser, Pieter Jelle, Reus, Lianne M., Gobom, Johan, Jansen, Iris, Dicks, Ellen, van der Lee, Sven J., Tsolaki, Magda, Verhey, Frans R. J., Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Molinuevo, José Luís, Engelborghs, Sebastiaan, Freund-Levi, Yvonne, Froelich, Lutz, Sleegers, Kristel, Dobricic, Valerija, Lovestone, Simon, Streffer, Johannes, Vos, Stephanie J. B., Bos, Isabelle, Smit, August B., Blennow, Kaj, Scheltens, Philip, Teunissen, Charlotte E., Bertram, Lars, Zetterberg, Henrik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

30. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score

Author

Tomassen, Jori, den Braber, Anouk, van der Lee, Sven J., Reus, Lianne M., Konijnenberg, Elles, Carter, Stephen F., Yaqub, Maqsood, van Berckel, Bart N.M., Collij, Lyduine E., Boomsma, Dorret I., de Geus, Eco J.C., Scheltens, Philip, Herholz, Karl, Tijms, Betty M., and Visser, Pieter Jelle

Published
2022
Full Text
View/download PDF

31. Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia

Author

Lorenzini, Luigi, Ingala, Silvia, Wottschel, Viktor, Wink, Alle Meije, Mutsaerts, Henk JMM, Haller, Sven, Blennow, Kaj, O'Brien, John T., Frisoni, B. Giovanni, Chételat, Gael, Payoux, Pierre, Martinez-Lage, Pablo, Waldman, Adam, Wardlaw, Joanna, Ritchie, Craig, Gispert, Juan Domingo, Visser, Pieter Jelle, Scheltens, Philip, Barkhof, Frederik, and Tijms, Betty M.

Published
2022
Full Text
View/download PDF

32. Costs of diagnosing early Alzheimer's disease in three European memory clinic settings: Results from the precision medicine in Alzheimer's disease project.

Author

Wimo, Anders, Kirsebom, Bjørn‐Eivind, Timón‐Reina, Santiago, Vromen, Ellen, Selnes, Per, Bon, Jaka, Emersic, Andreja, Kramberger, Milica Gregoric, Speh, Andreja, Visser, Pieter Jelle, Winblad, Bengt, and Fladby, Tormod

Subjects
ALZHEIMER'S disease diagnosis, CEREBROSPINAL fluid examination, COST effectiveness, COGNITIVE testing, RESEARCH funding, MAGNETIC resonance imaging, POSITRON emission tomography, DESCRIPTIVE statistics, APOLIPOPROTEINS, EARLY diagnosis, INDIVIDUALIZED medicine, CONFIDENCE intervals, MEDICAL care costs, BIOMARKERS
Abstract

Objectives: The implementation of disease‐modifying treatments for Alzheimer's Disease (AD) will require cost‐effective diagnostic processes. As part of The Precision Medicine In AD consortium (PMI‐AD) project, the aim is to analyze the baseline costs of diagnosing early AD at memory clinics in Norway, Slovenia, and the Netherlands. Methods: The costs of cognitive testing and a clinical examination, apolipoprotein E, magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), positron emission tomography and blood‐based biomarkers (BBM), which are used in different combinations in the three countries, were analyzed. Standardized unit costs, adjusted for GDP per capita and based on Swedish conditions were applied. The costs were expressed in euros (€) as of 2019. A diagnostic set comprising clinical examination, cognitive testing, MRI and CSF was defined as the gold standard, with MRI mainly used as an exclusion filter. Results: Cost data were available for 994 persons in Norway, 169 in Slovenia and 1015 in the Netherlands. The mean diagnostic costs were 1478 (95% confidence interval 1433–1523) € in Norway, 851 (731–970) € in Slovenia and 1184 (1135–1232) € in the Netherlands. Norway had the highest unit costs but also the greatest use of tests. With a uniform diagnostic test set applied, the diagnostic costs were 1264 (1238–1291) €, in Norway, 843 (771–914) € in Slovenia and 1184 (1156–1213) € in the Netherlands. There were no major cost differences between the final set of diagnoses. Conclusions: The total costs for setting a diagnosis of AD varied somewhat in the three countries, depending on unit costs and use of tests. These costs are relatively low in comparison to the societal costs of AD. Key points: The introduction of blood‐based biomarkers for detecting Alzheimer's Disease (AD) can change the diagnostic process.Given the expected demands for treatment of cognitive disorders such as AD, the costs and capacity of the diagnostic work‐up are of great importance for care funders and planners.Our study incorporating diagnostic costs from three distinct European regions provides valuable inputs for cost‐effectiveness studies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Detecting functional decline from normal ageing to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire

Author

Jutten, Roos J., Peeters, Carel F. W., Leijdesdorff, Sophie M. J., Visser, Pieter Jelle, Maier, Andrea B., Terwee, Caroline B., Scheltens, Philip, and Sikkes, Sietske A. M.

Subjects
Quantitative Biology - Neurons and Cognition
Abstract

INTRODUCTION: Detecting functional decline from normal ageing to dementia is relevant for diagnostic and prognostic purposes. Therefore, the Amsterdam IADL Questionnaire (A-IADL-Q) was developed: a 70-item proxy-based tool with good psychometric properties. We aimed to design a short version whilst preserving its psychometric quality. METHODS: Study partners of subjects (n=1355), ranging from cognitively normal to dementia subjects, completed the original A-IADL-Q. We selected the short version items using a stepwise procedure combining missing data, Item Response Theory and input from respondents and experts. We investigated internal consistency of the short version as well as concordance with the original version. To assess its construct validity, we additionally investigated concordance between the short version and the Mini-Mental State Examination (MMSE) and Disability Assessment for Dementia (DAD). Lastly, we investigated differences in IADL scores between diagnostic groups across the dementia spectrum. RESULTS: We selected 30 items covering the entire spectrum of IADL functioning. Internal consistency (.98) and concordance with the original version (.97) were very high. Concordance with the MMSE (.72) and DAD (.87) scores was high. IADL impairment scores increased across the spectrum from normal cognition to dementia. DISCUSSION: The A-IADL-Q Short Version (A-IADL-Q-SV) consists of 30 items. The A-IADL-Q-SV has maintained the psychometric quality of the original A-IADL-Q. As such, it is a concise measure of functional decline., Comment: 14 pages, 3 tables, 4 figures

Published
2016
Full Text
View/download PDF

34. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia

Author

Jansen, Willemijn J, Ossenkoppele, Rik, Tijms, Betty M, Fagan, Anne M, Hansson, Oskar, Klunk, William E, van der Flier, Wiesje M, Villemagne, Victor L, Frisoni, Giovanni B, Fleisher, Adam S, Lleó, Alberto, Mintun, Mark A, Wallin, Anders, Engelborghs, Sebastiaan, Na, Duk L, Chételat, Gäel, Molinuevo, José Luis, Landau, Susan M, Mattsson, Niklas, Kornhuber, Johannes, Sabri, Osama, Rowe, Christopher C, Parnetti, Lucilla, Popp, Julius, Fladby, Tormod, Jagust, William J, Aalten, Pauline, Lee, Dong Young, Vandenberghe, Rik, de Oliveira, Catarina Resende, Kapaki, Elisabeth, Froelich, Lutz, Ivanoiu, Adrian, Gabryelewicz, Tomasz, Verbeek, Marcel M, Sanchez-Juan, Páscual, Hildebrandt, Helmut, Camus, Vincent, Zboch, Marzena, Brooks, David J, Drzezga, Alexander, Rinne, Juha O, Newberg, Andrew, de Mendonça, Alexandre, Sarazin, Marie, Rabinovici, Gil D, Madsen, Karine, Kramberger, Milica G, Nordberg, Agneta, Mok, Vincent, Mroczko, Barbara, Wolk, David A, Meyer, Philipp T, Tsolaki, Magda, Scheltens, Philip, Verhey, Frans RJ, Visser, Pieter Jelle, Aarsland, Dag, Alcolea, Daniel, Alexander, Myriam, Almdahl, Ina S, Arnold, Steven E, Baldeiras, Inês, Barthel, Henryk, van Berckel, Bart NM, Blennow, Kaj, van Buchem, Mark A, Cavedo, Enrica, Chen, Kewei, Chipi, Elena, Cohen, Ann D, Förster, Stefan, Fortea, Juan, Frederiksen, Kristian S, Freund-Levi, Yvonne, Gkatzima, Olymbia, Gordon, Mark Forrest, Grimmer, Timo, Hampel, Harald, Hausner, Lucrezia, Hellwig, Sabine, Herukka, Sanna-Kaisa, Johannsen, Peter, Klimkowicz-Mrowiec, Aleksandra, Köhler, Sebastian, Koglin, Norman, van Laere, Koen, de Leon, Mony, Lisetti, Viviana, Maier, Wolfgang, Marcusson, Jan, Meulenbroek, Olga, Møllergård, Hanne M, Morris, John C, Nordlund, Arto, Novak, Gerald P, Paraskevas, George P, Perera, Gayan, Peters, Oliver, and Ramakers, Inez HGB

Subjects
Health Services and Systems, Health Sciences, Acquired Cognitive Impairment, Alzheimer's Disease Related Dementias (ADRD), Neurosciences, Aging, Dementia, Brain Disorders, Behavioral and Social Science, Neurodegenerative, Alzheimer's Disease, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Neurological, Mental health, Aged, Alzheimer Disease, Amyloid beta-Peptides, Brain, Cognition Disorders, Cognitive Dysfunction, Cross-Sectional Studies, Female, Humans, Male, Memory, Episodic, Mental Status and Dementia Tests, Middle Aged, Positron-Emission Tomography, Reference Values, Amyloid Biomarker Study Group, Other Medical and Health Sciences, Psychology, Cognitive Sciences, Clinical sciences, Clinical and health psychology
Abstract

ImportanceCerebral amyloid-β aggregation is an early event in Alzheimer disease (AD). Understanding the association between amyloid aggregation and cognitive manifestation in persons without dementia is important for a better understanding of the course of AD and for the design of prevention trials.ObjectiveTo investigate whether amyloid-β aggregation is associated with cognitive functioning in persons without dementia.Design, setting, and participantsThis cross-sectional study included 2908 participants with normal cognition and 4133 with mild cognitive impairment (MCI) from 53 studies in the multicenter Amyloid Biomarker Study. Normal cognition was defined as having no cognitive concerns for which medical help was sought and scores within the normal range on cognitive tests. Mild cognitive impairment was diagnosed according to published criteria. Study inclusion began in 2013 and is ongoing. Data analysis was performed in January 2017.Main outcomes and measuresGlobal cognitive performance as assessed by the Mini-Mental State Examination (MMSE) and episodic memory performance as assessed by a verbal word learning test. Amyloid aggregation was measured with positron emission tomography or cerebrospinal fluid biomarkers and dichotomized as negative (normal) or positive (abnormal) according to study-specific cutoffs. Generalized estimating equations were used to examine the association between amyloid aggregation and low cognitive scores (MMSE score ≤27 or memory z score≤-1.28) and to assess whether this association was moderated by age, sex, educational level, or apolipoprotein E genotype.ResultsAmong 2908 persons with normal cognition (mean [SD] age, 67.4 [12.8] years), amyloid positivity was associated with low memory scores after age 70 years (mean difference in amyloid positive vs negative, 4% [95% CI, 0%-7%] at 72 years and 21% [95% CI, 10%-33%] at 90 years) but was not associated with low MMSE scores (mean difference, 3% [95% CI, -1% to 6%], P = .16). Among 4133 patients with MCI (mean [SD] age, 70.2 [8.5] years), amyloid positivity was associated with low memory (mean difference, 16% [95% CI, 12%-20%], P

Published
2018

37. The Dementias Platform UK (DPUK) Data Portal

Author

Bauermeister, Sarah, Orton, Christopher, Thompson, Simon, Barker, Roger A., Bauermeister, Joshua R., Ben-Shlomo, Yoav, Brayne, Carol, Burn, David, Campbell, Archie, Calvin, Catherine, Chandran, Siddharthan, Chaturvedi, Nishi, Chêne, Geneviève, Chessell, Iain P., Corbett, Anne, Davis, Daniel H. J., Denis, Mike, Dufouil, Carole, Elliott, Paul, Fox, Nick, Hill, Derek, Hofer, Scott M., Hu, Michele T., Jindra, Christoph, Kee, Frank, Kim, Chi-Hun, Kim, Changsoo, Kivimaki, Mika, Koychev, Ivan, Lawson, Rachael A., Linden, Gerry J., Lyons, Ronan A., Mackay, Clare, Matthews, Paul M., McGuiness, Bernadette, Middleton, Lefkos, Moody, Catherine, Moore, Katrina, Na, Duk L., O’Brien, John T., Ourselin, Sebastien, Paranjothy, Shantini, Park, Ki-Soo, Porteous, David J., Richards, Marcus, Ritchie, Craig W., Rohrer, Jonathan D., Rossor, Martin N., Rowe, James B., Scahill, Rachael, Schnier, Christian, Schott, Jonathan M., Seo, Sang W., South, Matthew, Steptoe, Matthew, Tabrizi, Sarah J., Tales, Andrea, Tillin, Therese, Timpson, Nicholas J., Toga, Arthur W., Visser, Pieter-Jelle, Wade-Martins, Richard, Wilkinson, Tim, Williams, Julie, Wong, Andrew, and Gallacher, John E. J.

Published
2020

38. Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study

Author

Ribaldi, Federica, Altomare, Daniele, Jovicich, Jorge, Ferrari, Clarissa, Picco, Agnese, Pizzini, Francesca Benedetta, Soricelli, Andrea, Mega, Anna, Ferretti, Antonio, Drevelegas, Antonios, Bosch, Beatriz, Müller, Bernhard W., Marra, Camillo, Cavaliere, Carlo, Bartrés-Faz, David, Nobili, Flavio, Alessandrini, Franco, Barkhof, Frederik, Gros-Dagnac, Helene, Ranjeva, Jean-Philippe, Wiltfang, Jens, Kuijer, Joost, Sein, Julien, Hoffmann, Karl-Titus, Roccatagliata, Luca, Parnetti, Lucilla, Tsolaki, Magda, Constantinidis, Manos, Aiello, Marco, Salvatore, Marco, Montalti, Martina, Caulo, Massimo, Didic, Mira, Bargallo, Núria, Blin, Olivier, Rossini, Paolo M, Schonknecht, Peter, Floridi, Piero, Payoux, Pierre, Visser, Pieter Jelle, Bordet, Régis, Lopes, Renaud, Tarducci, Roberto, Bombois, Stephanie, Hensch, Tilman, Fiedler, Ute, Richardson, Jill C., Frisoni, Giovanni B., and Marizzoni, Moira

Published
2021
Full Text
View/download PDF

41. CSF cutoffs for MCI due to AD depend on APOEε4 carrier status

Author

Marizzoni, Moira, Ferrari, Clarissa, Babiloni, Claudio, Albani, Diego, Barkhof, Frederik, Cavaliere, Libera, Didic, Mira, Forloni, Gianluigi, Fusco, Federica, Galluzzi, Samantha, Hensch, Tilman, Jovicich, Jorge, Marra, Camillo, Molinuevo, José Luis, Nobili, Flavio, Parnetti, Lucilla, Payoux, Pierre, Ranjeva, Jean-Philippe, Ribaldi, Federica, Rolandi, Elena, Rossini, Paolo Maria, Salvatore, Marco, Soricelli, Andrea, Tsolaki, Magda, Visser, Pieter Jelle, Wiltfang, Jens, Richardson, Jill C., Bordet, Régis, Blin, Olivier, and Frisoni, Giovanni B.

Published
2020
Full Text
View/download PDF

42. Contributions of amyloid beta and cerebral small vessel disease in clinical decline

Author

Moonen, Justine E. F., primary, Haan, Renée, additional, Bos, Isabelle, additional, Teunissen, Charlotte, additional, van de Giessen, Elsmarieke, additional, Tomassen, Jori, additional, den Braber, Anouk, additional, van der Landen, Sophie M., additional, de Geus, Eco J. C., additional, Legdeur, Nienke, additional, van Harten, Argonde C., additional, Trieu, Calvin, additional, de Boer, Casper, additional, Kroeze, Lior, additional, Barkhof, Frederik, additional, Visser, Pieter Jelle, additional, and van der Flier, Wiesje M., additional

Published
2023
Full Text
View/download PDF

43. Longitudinal tau binding in tau‐PET negative patients with clinical Alzheimer’s disease

Author

Rikken, Roos M., primary, Coomans, Emma M., additional, de Koning, Lotte A., additional, Visser, Denise, additional, Verfaillie, Sander C.J., additional, den Braber, Anouk, additional, Collij, Lyduine E., additional, Golla, Sandeep S.V., additional, Barkhof, Frederik, additional, Visser, Pieter Jelle, additional, Scheltens, Philip, additional, van der Flier, Wiesje M., additional, Boellaard, Ronald, additional, Ossenkoppele, Rik, additional, van Berckel, Bart N.M., additional, Vijverberg, Everard G.B., additional, and van de Giessen, Elsmarieke, additional

Published
2023
Full Text
View/download PDF

44. Amyloid‐PET Centiloid quantification predicts cognitive functioning in a pre‐dementia population: findings from AMYPAD‐PNHS

Author

García, David Vállez, primary, Collij, Lyduine E., additional, Mastenbroek, Sophie E, additional, Alves, Isadora Lopes, additional, Gispert, Juan Domingo, additional, Jessen, Frank, additional, Ritchie, Craig W, additional, Rovira, Mercè Boada, additional, Marquié, Marta, additional, Vandenberghe, Rik, additional, Schöll, Michael, additional, Frisoni, Giovanni B, additional, Hanseeuw, Bernard J, additional, Payoux, Pierre, additional, Vellas, Bruno, additional, Dubois, Bruno, additional, Martinez‐Lage, Pablo, additional, Scheltens, Philip, additional, Shekari, Mahnaz, additional, Wolz, Robin, additional, Grootoonk, Sylke, additional, Stephens, Andrew W., additional, Gismondi, Rossella, additional, Schmidt, Mark E, additional, Buckley, Christopher, additional, Ford, Lisa, additional, Visser, Pieter Jelle, additional, Farrar, Gill, additional, and Barkhof, Frederik, additional

Published
2023
Full Text
View/download PDF

46. Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort

Author

Bocancea, Diana I., primary, den Braber, Anouk, additional, Jiang, Chenyang, additional, Coomans, Emma M., additional, van Unnik, Annemartijn A. J. M., additional, van Veen, Julia M.L., additional, Ribberink, Marieke, additional, Reijner, Niels, additional, Saddal, Shalina, additional, Mastenbroek, Sophie E, additional, van Gils, Aniek M., additional, Kluin, Caro M., additional, de Leeuw, Diederick Martijn, additional, Vromen, Eleonora M., additional, Bekkers, Lotta, additional, Georgallidou, Margarita, additional, van der Landen, Sophie M., additional, Baumann, Jana M., additional, Heuvelink, Joost, additional, Reus, Lianne M., additional, Lorenzini, Luigi, additional, Kamps, Suzie, additional, Bouman, Sophie P.H., additional, Singleton, Ellen Hanna, additional, de Boer, Sterre C.M., additional, Rousset, Rebecca Z., additional, Kuijper, Bart, additional, Verhagen, Eline, additional, Smit, Dimas, additional, Rikken, Roos M., additional, Visser, Pieter Jelle, additional, Bouwman, Femke H., additional, Barkhof, Frederik, additional, Lemstra, Afina W., additional, Pijnenburg, Yolande A.L., additional, van der Flier, Wiesje M., additional, Venkatraghavan, Vikram, additional, and Tijms, Betty M., additional

Published
2023
Full Text
View/download PDF

47. APOE‐dependent and ‐independent polygenic pathways determining early Alzheimer’s Disease pathological changes in CSF and MRI

Author

Lorenzini, Luigi, primary, Collij, Lyduine E., additional, Tesi, Niccoló, additional, Ingala, Silvia, additional, Sudre, Carole H, additional, Wolz, Robin, additional, Haller, Sven, additional, Blennow, Kaj, additional, Frisoni, Giovanni B, additional, Payoux, Pierre, additional, Martinez‐Lage, Pablo, additional, Ewers, Michael, additional, Chetelat, Gael, additional, Ritchie, Craig W, additional, Gispert, Juan Domingo, additional, Mutsaerts, Henk‐Jan, additional, Altmann, Andre, additional, Tijms, Betty M., additional, Wink, Alle Meije, additional, Visser, Pieter Jelle, additional, and Barkhof, Frederik, additional

Published
2023
Full Text
View/download PDF

48. Hyperspectral retinal imaging as a biomarker for Alzheimer’s disease

Author

Thach, Michelle, primary, de Ruyter, Frederique J. Hart, additional, Curro‐Tafili, Katie R., additional, van de Giessen, Elsmarieke, additional, Collij, Lyduine E., additional, den Braber, Anouk, additional, Tan, H. Stevie, additional, Visser, Pieter Jelle, additional, Verbraak, Frank D., additional, Osseiran, Sam, additional, Grondin, Jean‐Sébastien, additional, Orellina, Julie Antonelle, additional, Campbell, Shannon, additional, Chevrefils, Claudia, additional, Sylvestre, Jean‐Philippe, additional, and Bouwman, Femke H., additional

Published
2023
Full Text
View/download PDF

49. Differential associations between regional amyloid PET and Alzheimer’s disease polygenic risk scores

Author

Luckett, Emma S., primary, Collij, Lyduine E., additional, Lorenzini, Luigi, additional, Tesi, Niccoló, additional, Vilor‐Tejedor, Natalia, additional, García, David Vállez, additional, Alves, Isadora Lopes, additional, Shekari, Mahnaz, additional, Wink, Alle Meije, additional, Payoux, Pierre, additional, Dubois, Bruno, additional, Grau‐Rivera, Oriol, additional, Boada, Mercè, additional, Nordberg, Agneta K, additional, Scheltens, Philip, additional, Schöll, Michael, additional, Wolz, Robin, additional, Schmidt, Mark E, additional, Gismondi, Rossella, additional, Stephens, Andrew W., additional, Buckley, Christopher, additional, Frisoni, Giovanni B, additional, Hanseeuw, Bernard J, additional, Visser, Pieter Jelle, additional, Vandenberghe, Rik, additional, Farrar, Gill, additional, Gispert, Juan Domingo, additional, Ritchie, Craig W, additional, and Barkhof, Frederik, additional

Published
2023
Full Text
View/download PDF

50. The association between Aβ aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort

Author

Régy, Mélina, primary, Quenon, Lisa, additional, Collij, Lyduine E., additional, García, David Vállez, additional, Gérard, Thomas, additional, Frisoni, Giovanni, additional, Scheltens, Philip, additional, Schöll, Michael, additional, Vandenberghe, Rik, additional, Boada, Mercè, additional, Marquié, Marta, additional, Payoux, Pierre, additional, Nordberg, Agneta K, additional, Kivipelto, Miia, additional, Walker, Zuzana, additional, Dubois, Bruno, additional, Boutoleau‐Bretonnière, Claire, additional, Pasquier, Florence, additional, Dugravot, Aline, additional, Gabelle, Audrey, additional, Visser, Pieter Jelle, additional, Grau‐Rivera, Oriol, additional, Martinez‐Lage, Pablo, additional, Ritchie, Craig W, additional, Wolz, Robin, additional, Farrar, Gill, additional, Lhommel, Renaud, additional, Barkhof, Frederik, additional, Dumurgier, Julien, additional, and Hanseeuw, Bernard J, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results